Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 28, 2019Open Forum Infectious DiseasesOpen Access

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

View Full Paper
Ask AI
Bookmark
Share

Authors

CCCornelius J. ClancyBPBrian A. PotoskiDBDeanna J. Buehrle

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Clancy et al. (2019) studied this question.

synapsesocial.com/papers/6a996a9d96b2e868bfe11d64https://doi.org/10.1093/ofid/ofz344
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations2018 · 168 citations
  2. 2Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis2017 · 230 citations
  3. 3Mutations in<i>bla</i><sub>KPC-3</sub>That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases2017 · 194 citations
  4. 4Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance: Table 1.2016 · 46 citations
  5. 5Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms2016 · 256 citations